@article{c7de1219de0f46ba8c9d1d8c0cc3bc00,
title = "Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients",
keywords = "Awards and Prizes, COVID-19, Humans, SARS-CoV-2",
author = "{van Kempen}, {Zo{\'e} L. E.} and Joep Killestein and Hans-Peter Hartung",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ZK reports no disclosures. JK reports speaking and consulting relationships with Biogen, Genzyme, Merck, Novartis, Roche, Sanofi, and TEVA. Amsterdam UMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Sanofi, and TEVA. HPH reports fees for serving on steering and data monitoring committees from BayerHealthcare, Biogen, BMS Celgene, GeNeuro, Merck, Novartis, Roche, Sanofi, TG Therapeutics, and VielaBio Horizon Therapeutics.",
year = "2021",
month = dec,
day = "1",
doi = "https://doi.org/10.1177/13524585211057511",
language = "English",
volume = "27",
pages = "2123--2125",
journal = "Multiple sclerosis (Houndmills, Basingstoke, England)",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "14",
}